<DOC>
	<DOCNO>NCT02706886</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics pharmacodynamics single- multiple-ascending dos ALN-GO1 healthy adult volunteer subject PH1 .</brief_summary>
	<brief_title>Study ALN-GO1 Healthy Adult Subjects Patients With Primary Hyperoxaluria Type 1</brief_title>
	<detailed_description />
	<mesh_term>Hyperoxaluria , Primary</mesh_term>
	<criteria>Inclusion Criteria Parts A B : Women child bear potential must negative pregnancy test , breastfeeding , must willing use contraception . Willing provide write informed consent comply study requirement . Additional Inclusion Criteria Part B : Confirmation PH1 disease Meet 24 hour urine oxalate excretion requirement Estimated GFR &gt; 45 mL/min/1.73m2 . If take Vitamin B6 ( pyridoxine ) , must stable regimen least 90 day Exclusion Criteria Parts A B : No clinically significant health concern ( exception PH1 patient Part B ) Clinically significant ECG abnormality Abnormal AST/ALT clinical safety laboratory result consider clinically significant Received investigational agent within 3 month first dose study drug followup another clinical study Known history allergic reaction oligonucleotide GalNAc History intolerance subcutaneous injection</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PH1</keyword>
	<keyword>Primary Hyperoxaluria</keyword>
	<keyword>RNAi therapeutic</keyword>
	<keyword>siRNA</keyword>
	<keyword>AGT</keyword>
</DOC>